Timely clinical updates and thought leadership on new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and generics introduced to the market. For questions regarding new updates, please email clinical@myMatrixx.com.
News and Updates
FDA Recalls More than 7000 Bottles of Duloxetine
November 06, 2024
The U.S. Food and Drug Administration (FDA) has announced a voluntary, manufacturer-initiated recall of more than 7,000 bottles of duloxetine delayed-release capsules due to unacceptable levels of a potential carcinogen.
Learn more
ODG adopts formulary updates effective November 1, 2024
October 25, 2024
ODG by MCG has adopted updates to its ODG Drug Formulary, which includes U.S. Food and Drug Administration (FDA) approved drugs listed by generic and/or brand names that are commonly prescribed for workplace injuries.
Learn more
FDA Approves Nalmefene Auto-Injector to Reverse Opioid Overdose
August 14, 2024
On August 7, 2024, the U.S. Food and Drug Administration (FDA) approved Purdue Pharma's Zurnai® (nalmefene) autoinjector for emergency treatment of opioid overdose in individuals aged 12 years and older.
Learn more
Mislabeling Leads to Voluntary Clonazepam Recall
July 22, 2024
On July 16, 2024, Endo USA, Inc. voluntarily recalled a single lot of Clonazepam 0.125 mg and 0.25 mg Orally Disintegrating tablets (ODT) due to a packaging error.
Learn more
ODG Formulary Updates for “Y” and “N” Drugs
July 22, 2024
Effective July 26, 2024, ODG by MCG is updating Appendix A − its drug formulary – with the following medication edits to both the preferred, first-line “Y” drugs, and drugs that are not recommended as a first-line treatment known as “N” drugs.
Learn more
Q2 2024 New Drug Report (April-June)
July 11, 2024
Read our new Q2 2024 (January through March) pipeline report that features new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations.
Learn more